全文获取类型
收费全文 | 2177篇 |
免费 | 189篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 73篇 |
妇产科学 | 16篇 |
基础医学 | 255篇 |
口腔科学 | 18篇 |
临床医学 | 211篇 |
内科学 | 305篇 |
皮肤病学 | 37篇 |
神经病学 | 144篇 |
特种医学 | 264篇 |
外科学 | 278篇 |
综合类 | 109篇 |
一般理论 | 2篇 |
预防医学 | 204篇 |
眼科学 | 95篇 |
药学 | 172篇 |
中国医学 | 2篇 |
肿瘤学 | 140篇 |
出版年
2021年 | 35篇 |
2020年 | 19篇 |
2019年 | 31篇 |
2018年 | 44篇 |
2017年 | 20篇 |
2016年 | 30篇 |
2015年 | 22篇 |
2014年 | 51篇 |
2013年 | 54篇 |
2012年 | 81篇 |
2011年 | 107篇 |
2010年 | 64篇 |
2009年 | 61篇 |
2008年 | 96篇 |
2007年 | 98篇 |
2006年 | 94篇 |
2005年 | 87篇 |
2004年 | 105篇 |
2003年 | 75篇 |
2002年 | 60篇 |
2001年 | 51篇 |
2000年 | 48篇 |
1999年 | 41篇 |
1998年 | 48篇 |
1997年 | 27篇 |
1996年 | 34篇 |
1995年 | 26篇 |
1994年 | 32篇 |
1993年 | 26篇 |
1992年 | 47篇 |
1991年 | 47篇 |
1990年 | 60篇 |
1989年 | 56篇 |
1988年 | 54篇 |
1987年 | 39篇 |
1986年 | 52篇 |
1985年 | 30篇 |
1984年 | 24篇 |
1983年 | 23篇 |
1982年 | 19篇 |
1981年 | 18篇 |
1980年 | 20篇 |
1979年 | 22篇 |
1978年 | 20篇 |
1973年 | 21篇 |
1972年 | 23篇 |
1971年 | 19篇 |
1969年 | 18篇 |
1968年 | 24篇 |
1967年 | 24篇 |
排序方式: 共有2374条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.
75.
Multiple injections of leukoreduced platelet rich plasma reduce pain and functional impairment in a canine model of ACL and meniscal deficiency 下载免费PDF全文
James L. Cook Patrick A. Smith Chantelle C. Bozynski Keiichi Kuroki Cristi R. Cook Aaron M. Stoker Ferris M. Pfeiffer 《Journal of orthopaedic research》2016,34(4):607-615
Platelet rich plasma (PRP) is used to treat many musculoskeletal disorders. We used a canine model to determine the effects of multiple intra‐articular injections of leukoreduced PRP (ACP) on anterior cruciate ligament healing, meniscal healing, and progression of osteoarthritis (OA). With Animal Care and Use Committee (ACUC) approval, 12 dogs underwent partial ACL transection and meniscal release in one knee. At weeks 1, 2, 3, 6, and 8 after insult, dogs were treated with intra‐articular injections (2 ml) of either ACP (n = 6) or saline (n = 6). Dogs were assessed over 6 months to determine comfortable range of motion (CROM), lameness, pain, effusion, kinetics, and radiographic and arthroscopic assessments. At 6‐month endpoint, dogs were assessed for ACL material properties and histopathology. Saline‐treated dogs had significantly (p < 0.04) more CROM loss, significantly (p < 0.01) more pain, significantly (p < 0.05) more severe lameness, significantly (p < 0.05) lower function, and significantly (p < 0.05) lower %Total Pressure Index in affected hindlimbs compared to ACP‐treated dogs. Radiographic OA increased significantly (p < 0.01) over time within each group. Arthroscopically, saline‐treated knees showed moderate to severe synovitis, further ACL disruption, and medial compartment cartilage loss, and ACP‐treated knees showed evidence of ACL repair and less severe synovitis. ACL material properties in ACP‐treated knees were closer to normal than in saline‐treated knees, however, the differences were not statistically significant. ACL histopathology was significantly (p< 0.05) less severe in ACP‐treated knees compared to saline‐treated knees. Five intra‐articular injections of leukoreduced PRP had beneficial effects for ACL healing, improved range of motion, decreased pain, and improved limb function for up to 6 months in this model. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:607–615, 2016. 相似文献
76.
77.
Insulin receptors, as well as IGF-1 receptors and their postreceptor signaling partners, are distributed throughout the brain. Insulin acts on these receptors to modulate peripheral metabolism, including regulation of appetite, reproductive function, body temperature, white fat mass, hepatic glucose output, and response to hypoglycemia. Insulin signaling also modulates neurotransmitter channel activity, brain cholesterol synthesis, and mitochondrial function. Disruption of insulin action in the brain leads to impairment of neuronal function and synaptogenesis. In addition, insulin signaling modulates phosphorylation of tau protein, an early component in the development of Alzheimer disease. Thus, alterations in insulin action in the brain can contribute to metabolic syndrome, and the development of mood disorders and neurodegenerative diseases. 相似文献
78.
Marion E Couch Robert L Ferris Joseph A Brennan Wayne M Koch Elizabeth M Jaffee Michael S Leibowitz Gerald T Nepom Henry A Erlich David Sidransky 《Clinical cancer research》2007,13(23):7199-7206
PURPOSE: To determine if serologic recognition of p53 mutations at the protein level depends upon the ability of mutant p53 to express new peptide epitopes that bind to human leukocyte antigen (HLA) class II molecules, we used anti-p53 antibody production as a marker for HLA class II-restricted T-cell involvement in head and neck cancer. EXPERIMENTAL DESIGN: An anti-p53 antibody response was correlated with specific p53 mutations and the patients' HLA class II alleles and haplotypes. HLA binding studies and in vitro stimulation (IVS) of peripheral blood mononuclear cells were done using a mutant versus wild-type HLA-DQ7-binding p53 peptide. RESULTS: Certain HLA-DQ and HLA-DR alleles were frequently present in p53 seropositive patients who produced serum anti-p53 antibodies. Selected mutated p53 peptides fit published allele-specific HLA class II binding motifs for the HLA-DQ7 or HLA-DR1 molecules. Moreover, a mutant p53 peptide bound with a 10-fold greater affinity than the wild-type p53 peptide to HLA-DQ7 molecules. IVS of CD4(+) T cells from seven healthy HLA-DQ7(+) donors using this mutant p53 peptide (p53(220C)) was associated with a partial T helper type 2 phenotype compared with IVS using the wild-type p53(210-223) peptide. CONCLUSIONS: Our results support the hypothesis that mutated p53 neoantigens can bind to specific HLA class II molecules, leading to a break in tolerance. This may lead to skewing of the CD4(+) T lymphocyte response toward a tumor-permissive T helper type 2 profile in head and neck cancer patients, as manifested by seropositivity for p53. 相似文献
79.
Daron G Ferris Jennifer L Waller Ashley Owen Jozette Smith 《Journal of the American Board of Family Medicine》2008,21(1):31-37
OBJECTIVE: To determine correlates of human papillomavirus (HPV) vaccine acceptance in mid-adult women. METHODS: A convenience sample of 472 mid-adult women completed a 2-part, 69-item survey that included demographic, knowledge, and behavioral variables as potential correlates of vaccine acceptance. Univariable and multivariable logistic regression models were used to identify correlates for vaccine acceptance. RESULTS: Mid-adult women who received the HPV vaccine were more likely to be younger than 55 years (P < .001); have had an abnormal Papanicolaou test (odds ratio [OR], 2.15; 95% CI, 1.18-3.92); understand that HPV causes cervical cancer (OR, 2.39; 95% CI, 1.08-5.30); feel at risk for HPV infection (OR, 2.14; 95% CI, 1.00-4.57), and feel it is important for their partner (OR, 25.20; 95% CI, 9.66-65.72) and children (OR, 3.54; CI, 0.51-24.56) to get the HPV vaccine. Monogamous mid-adult women (OR, 0.46; 95% CI, 0.21-1.00); women who did not want any vaccines (OR, 0.26; 95% CI, 0.07-0.92); and women who felt it was too late to get the vaccine (OR, 0.18; 95% CI, 0.08-0.44) were less likely to want the HPV vaccine. CONCLUSIONS: These clinical predictors of HPV vaccine acceptance will help clinicians recognize mid-adult women who may be more receptive to vaccination. 相似文献
80.
Anthony MA Smith Marian K Pitts Julia M Shelley Juliet Richters Jason Ferris 《BMC public health》2007,7(1):139